Infection incidence, timing and dose dependency in rheumatoid arthritis patients treated with rituximab: a retrospective cohort study
Main finding · Infection incidence rateResult — go to the resultAdjusted incidence rate ratio 0.35 95% CI 0.17–0.72Authors' conclusion
Ultra-low dosing (200 mg) of RTX is associated with a lower risk of infections in RA.
Study context
- Population
- RA patients treated with rituximab (RTX) 2012–2021 at the Sint Maartenskliniek1,254 patient years
- Participants
- 490 patients
- Exposure
- RTX 200 mg vs 500 mg vs 1000 mg per cycle
- Outcome
- Infection incidence rate
Methodological detailssingle-centre, mixed-effects Poisson regression
- Single-centre
- Mixed-effects Poisson regression
Main finding
As reported in the abstract
Adjusted incidence rate ratio
0.35
95% CI 0.17–0.72
P = 0.004
By group
200 mgvs 1000 mg
adjusted IRR 0.35 (95% CI 0.17–0.72); P = 0.004
Observational data: associations, not effects.
Further findings
Timing of infections (1000 or 500 mg)
- Infections seemed to occur more frequently within the first two months after infusion than later in the treatment cycle
Original publication
Infection incidence, timing and dose dependency in rheumatoid arthritis patients treated with rituximab: a retrospective cohort study. Rheumatology (Oxford). Published 6 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →